𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

✍ Scribed by Jens Benn Sørensen; Lars Stenbygaard; Lars Drivsholm; Per Dombernowsky; Heine H. Hansen

Publisher
Springer
Year
1993
Tongue
English
Weight
401 KB
Volume
32
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of esorubicin (4′deoxydox
Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer
✍ James R. Rigas; Mark G. Kris; Richard J. Gralla; Robert T. Heelan; Linda D. Mark 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 264 KB

Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m 2 intravenously) every 3 we

Phase II trial of 4′ deoxydoxorubicin (D
Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma
✍ Christopher Rose; Thomas E. Lad; Lary J. Kilton; Joel Schor; Steven T. Rosen; Ar 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 162 KB

A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four response